Crohn’s Disease (Regional Enteritis) – Pipeline Review, H2 2018
- Pages: 413
- Published: August 2018
- Report Code: GMDHC10692IDB
Global Markets Direct’s, ‘Crohn's Disease (Regional Enteritis) – Pipeline Review, H2 2018’, provides an overview of the Crohn's Disease (Regional Enteritis) pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Crohn's Disease (Regional Enteritis), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Crohn's Disease (Regional Enteritis) and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
– The report provides a snapshot of the global therapeutic landscape of Crohn's Disease (Regional Enteritis)
– The report reviews pipeline therapeutics for Crohn's Disease (Regional Enteritis) by companies and universities/research institutes based on information derived from company and industry-specific sources
– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
– The report reviews key players involved Crohn's Disease (Regional Enteritis) therapeutics and enlists all their major and minor projects
– The report assesses Crohn's Disease (Regional Enteritis) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
– The report summarizes all the dormant and discontinued pipeline projects
– The report reviews latest news related to pipeline therapeutics for Crohn's Disease (Regional Enteritis)
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Crohn's Disease (Regional Enteritis)
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Crohn's Disease (Regional Enteritis) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies mentioned
4D Pharma PLC
AbbVie Inc
Adello Biologics LLC
AlfaSigma SpA
Allergan Plc
Alpha Cancer Technologies Inc
Alteogen Inc
Alvotech Iceland
Amgen Inc
Antibe Therapeutics Inc
Aptevo Therapeutics Inc
Arena Pharmaceuticals Inc
Artelo Biosciences Inc
Arven Ilac
Atlantic Bio Sci LLC
Atlantic Healthcare Plc
Avexegen Therapeutics Inc
Bioleaders Corp
BioLingus AG
Biond Biologics Ltd
Boehringer Ingelheim GmbH
Bristol-Myers Squibb Co
Celgene Corp
Celltrion Inc
ChemoCentryx Inc
ChironWells GmbH
Chong Kun Dang Pharmaceutical Corp
Coherus BioSciences Inc
Commence Bio Inc
Concenter BioPharma Silkim Ltd
Daiichi Sankyo Co Ltd
DBV Technologies SA
EA Pharma Co Ltd
Eisai Co Ltd
Eli Lilly and Co
Enterome Bioscience SA
Enzo Biochem Inc
ETX Pharma Inc
Evelo Biosciences Inc
Ferring International Center SA
Fresenius SE & Co KGaA
FYB202 GmbH & Co KG
Galactica Biotech Ltd
Galapagos NV
Genentech Inc
Genor BioPharma Co Ltd
IB Pharmaceuticals Inc
Inception Sciences Inc
InDex Pharmaceuticals Holding AB
Innovation Pharmaceuticals Inc
Innovent Biologics Inc
Inspyr Therapeutics Inc
Johnson & Johnson
Jyant Technologies Inc
Kang Stem Biotech Co Ltd
Kyowa Hakko Kirin Co Ltd
Merck & Co Inc
Mesoblast Ltd
Mitsubishi Tanabe Pharma Corp
Mycenax Biotech Inc
Naia Ltd
Nichi-Iko Pharmaceutical Co Ltd
Nimbus Therapeutics LLC
Oncobiologics Inc
Oncodesign SA
OSE Immunotherapeutics
Paradigm Biopharmaceuticals Ltd
Pfizer Inc
Protagonist Therapeutics Inc
Protheragen Inc
Qu Biologics Inc
Re-Pharm Ltd
RedHill Biopharma Ltd
Reliance Life Sciences Pvt Ltd
Sandoz International GmbH
SATT North SAS
Scythian Biosciences Corp
Second Genome Inc
Seres Therapeutics Inc
Shire Plc
Soligenix Inc
Sublimity Therapeutics Ltd
Synedgen Inc
Synlogic Inc
TaiwanJ Pharmaceuticals Co Ltd
Takeda Pharmaceutical Co Ltd
Tetherex Pharmaceuticals Corp
The Cell-Factory BVBA
Theravance Biopharma Inc
Thetis Pharmaceuticals LLC
Tiziana Life Sciences Plc
Ventria Bioscience
Vivelix Pharmaceuticals Ltd
Xbrane Biopharma AB
Table of Contents
List of Tables
List of Figures
Pricing
Discounts available for multiple purchases.